[HTML][HTML] Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - Springer
Abstract Background Immunohistochemical (IHC) PD-L1 expression is commonly employed
as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - search.proquest.com
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
[HTML][HTML] Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically …
G Sigurjonsdottir, T De Marchi… - Breast Cancer …, 2023 - breast-cancer-research …
Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive
biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC …
biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - europepmc.org
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi… - Breast cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
[HTML][HTML] Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - ncbi.nlm.nih.gov
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - portal.research.lu.se
Background: Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger, J Hartman… - 2023 - researchsquare.com
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - lup.lub.lu.se
Background: Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established …
G Sigurjonsdottir, T De Marchi, A Ehinger… - Breast Cancer …, 2023 - europepmc.org
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …
predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC) …